STANDARD BIOTOOLS INC. 8-K

What Happened

• Standard BioTools Inc. (LAB) issued a press release on May 5, 2026 that disclosed certain financial results for the three months ended March 31, 2026. That press release was furnished as Exhibit 99.1 to a Form 8-K filed May 5, 2026.
• The Form 8-K (Items 2.02 and 7.01) incorporates the press release by reference, together with the press release’s forward‑looking statement disclaimer; the sections titled “Full Year 2026 Revenue Outlook” and “About Standard BioTools Inc.” were excluded from the incorporation.

Key Details

• Press release date: May 5, 2026 (attached as Exhibit 99.1).
• Reporting period: three months ended March 31, 2026 (Q1 2026).
• Items reported on Form 8-K: 2.02 (Results of Operations and Financial Condition) and 7.01 (Regulation FD Disclosure); exhibits include 99.1 and iXBRL cover page (Exhibit 104).
• The filing publicly disseminated material quarterly results under Regulation FD; the specific revenue/guidance items under the “Full Year 2026 Revenue Outlook” heading were not incorporated into the 8-K.

Why It Matters

• Investors should review the May 5 press release for the company’s reported quarterly performance and any forward‑looking statements (the filing incorporates the forward‑looking disclaimer). This is the company’s official public disclosure of Q1 2026 results.
• Because the filing excludes the “Full Year 2026 Revenue Outlook” text from incorporation, investors should check the press release and subsequent filings for any company guidance or updated full‑year revenue outlook.